Butterfly Network Earnings Call Highlights Turnaround Momentum

Butterfly Network, Inc. ((BFLY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Butterfly Network’s latest earnings call painted a picture of a company in the midst of a convincing turnaround. Management emphasized record revenue, expanding high-margin software sales, improving cash flow and a strengthened balance sheet, while acknowledging lingering losses, softer international demand and uncertainty around the timing of newer revenue streams like Embedded and home care.

Record Quarterly and Full-Year Revenue Growth

Butterfly delivered record Q4 2025 revenue of $31.5 million, up 41% year over year and the highest quarterly tally in its history. Full-year 2025 revenue reached $97.6 million, a 19% increase versus 2024, driven largely by rising core point-of-care ultrasound volumes and the first material contribution from Butterfly Embedded.

U.S. Market Leads the Surge

The U.S. business was the growth engine, with Q4 revenue climbing 55% to $26.8 million and unit sales up 44%. This domestic strength helped offset weakness abroad and underscored the traction Butterfly is gaining with hospitals and health systems looking to standardize on portable ultrasound.

Software and Services Take Center Stage

Software and other services continued to gain importance, generating $13.4 million in Q4 revenue, up 76% year over year. The software and services mix jumped to 43% of total revenue from 34% a year earlier, signaling a shift toward more recurring, higher-margin revenue that investors typically prize.

Margins Expand on Better Mix

Gross profit in Q4 rose 55% to $21.2 million, outpacing revenue growth and lifting gross margin to 67% from 61%. Management credited the improvement to richer Embedded revenue and lower software amortization, suggesting the business model is becoming structurally more profitable as it scales.

EBITDA Loss Narrows and Cash Flow Turns Positive

Butterfly’s adjusted EBITDA loss shrank to $3.2 million in Q4 from $9.1 million a year earlier, a 65% improvement, while the full-year loss improved 32% to $26.5 million. Notably, the company generated positive free cash flow of $6.3 million in Q4, an important milestone for a still-loss-making growth story.

Cash Burn Falls and Balance Sheet Stays Solid

Year-end cash, cash equivalents and restricted cash totaled $154.5 million, giving Butterfly ample liquidity to fund its roadmap. Cash use in 2025 dropped to $19.4 million from $45.9 million in 2024, the lowest annual cash burn in its history and a sign of tighter cost control and improving unit economics.

Midjourney Deal Anchors Embedded Strategy

A centerpiece of the call was the $74 million Midjourney contract, which added $6.8 million to Q4 revenue and underpins the Butterfly Embedded strategy. The partnership brings upfront payments, annual licenses, milestones and potential future chip and revenue-share upside, positioning Embedded as a long-term growth and margin driver.

Enterprise Pipeline and Product Adoption Build

On the enterprise side, the Compass AI launch in Q4 expanded the sales pipeline by more than 50%, and Butterfly closed a second large system-wide deal while posting record probe sales. These wins suggest deepening penetration in large health systems, a key channel for scaling both hardware and software offerings.

Regulatory and Security Wins Open Doors

The company hit several regulatory and security milestones, securing GovRAMP and TXRAMP approvals in the U.S., with FedRAMP expected next. Its HeartFocus application became the first FDA-cleared app in the Butterfly Garden in 2025, and a beam-steering API enabling 3D imaging for partners is slated for the first half of 2026.

Advancing the Chip Roadmap

Butterfly moved its fifth-generation P5.1 semiconductor into production by year-end, a key step in improving image quality and power efficiency. The next-generation Apollo architecture is in development, targeting roughly 20-times today’s data and compute performance, which could unlock new AI capabilities and deeper Embedded integrations.

International Markets Lag

Not all regions are firing equally, as international revenue fell 6% year over year to $4.7 million in Q4. Management cited product mix shifts as a contributor, highlighting that international execution remains a work in progress despite strong momentum at home.

iQ+ Weakness and Product Mix Transition

Sales of the legacy iQ+ device plunged 79% year over year in Q4, even as the newer iQ3 posted a 42% increase. While the shift reflects customer adoption of higher-end hardware, it also underscores the complexity of managing product transitions and maintaining overall volume growth.

Profitability Still Out of Reach

Despite visible improvement, Butterfly remains in the red with an adjusted EBITDA loss of $3.2 million in Q4 and $26.5 million for 2025. Management framed profitability as a medium-term goal, balancing ongoing investment in R&D and Embedded initiatives against steadily improving operating leverage.

Embedded and Home Care Timing Risks

The Midjourney deal is generating pre-commercial revenue today, but management stressed that major upside from commercialization, chip shipments and revenue sharing will skew toward later years of its five-year plan. Similarly, a home-care agreement expected in the first half of 2026 should bring only nominal revenue this year, with more meaningful contribution likely from late 2026 into 2027.

External Headwinds and Near-Term Seasonality

Tariffs introduced in 2025 are creating modest downward pressure and adding unpredictability, while prior government and FDA-related delays have weighed on purchasing cycles, though those effects are said to be easing. Q1 is seasonally weaker, and guidance calls for a temporary bump in expenses from payroll tax resets, retirement-plan costs and sales meetings.

Guidance Signals Continued Growth with Managed Losses

Management guided Q1 2026 revenue to $24–$28 million with an adjusted EBITDA loss of $8–$10 million, reflecting typical seasonality. For the full year, Butterfly expects $117–$121 million in revenue, implying 20%–24% growth, and an adjusted EBITDA loss of $21–$25 million as it continues to invest in Embedded, R&D and absorbs the modest impact of tariffs.

Butterfly Network’s call showcased a company leaning into its strengths: accelerating U.S. demand, a rising software mix, improving margins and a powerful Embedded partnership pipeline. While profitability remains out of reach and some growth levers will take time to fully monetize, the combination of lower cash burn, solid liquidity and clear strategic direction is likely to keep the stock on the radar of growth-oriented healthcare investors.